Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

GYRE

Gyre Therapeutics (GYRE)

Gyre Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:GYRE
日付受信時刻ニュースソース見出しコード企業名
2024/10/2305 : 05GlobeNewswire Inc.Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver FibrosisNASDAQ:GYREGyre Therapeutics Inc
2024/10/0205 : 05GlobeNewswire Inc.Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor ConferenceNASDAQ:GYREGyre Therapeutics Inc
2024/09/0621 : 31Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:GYREGyre Therapeutics Inc
2024/09/0621 : 15Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:GYREGyre Therapeutics Inc
2024/09/0505 : 05GlobeNewswire Inc.Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:GYREGyre Therapeutics Inc
2024/08/1319 : 00GlobeNewswire Inc.Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business UpdateNASDAQ:GYREGyre Therapeutics Inc
2024/08/0920 : 00GlobeNewswire Inc.Gyre Therapeutics to Present at Sidoti Virtual Investor ConferenceNASDAQ:GYREGyre Therapeutics Inc
2024/08/0905 : 31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GYREGyre Therapeutics Inc
2024/08/0905 : 05GlobeNewswire Inc.Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of DirectorsNASDAQ:GYREGyre Therapeutics Inc
2024/07/0305 : 05GlobeNewswire Inc.Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated ThrombocytopeniaNASDAQ:GYREGyre Therapeutics Inc
2024/06/1905 : 05GlobeNewswire Inc.Gyre Therapeutics Announces Publication in Journal of Gastroenterology and HepatologyNASDAQ:GYREGyre Therapeutics Inc
2024/06/1805 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GYREGyre Therapeutics Inc
2024/05/3105 : 06Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:GYREGyre Therapeutics Inc
2024/05/3105 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GYREGyre Therapeutics Inc
2024/05/3105 : 05GlobeNewswire Inc.Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial HypertensionNASDAQ:GYREGyre Therapeutics Inc
2024/05/3105 : 02Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:GYREGyre Therapeutics Inc
2024/05/2905 : 05GlobeNewswire Inc.Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® IndexesNASDAQ:GYREGyre Therapeutics Inc
2024/05/1405 : 07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GYREGyre Therapeutics Inc
2024/05/1005 : 10GlobeNewswire Inc.Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:GYREGyre Therapeutics Inc
2024/05/1005 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GYREGyre Therapeutics Inc
2024/05/0821 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GYREGyre Therapeutics Inc
2024/03/2619 : 00GlobeNewswire Inc.Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:GYREGyre Therapeutics Inc
2024/03/2120 : 00GlobeNewswire Inc.Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. NussbaumNASDAQ:GYREGyre Therapeutics Inc
2023/12/1523 : 04PR Newswire (US)Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B FundingNASDAQ:GYREGyre Therapeutics Inc
2023/11/1321 : 00GlobeNewswire Inc.Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver MeetingNASDAQ:GYREGyre Therapeutics Inc
2023/11/0306 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GYREGyre Therapeutics Inc
2023/11/0206 : 18Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:GYREGyre Therapeutics Inc
2023/11/0205 : 58Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:GYREGyre Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:GYRE